Jefferies has initiated coverage on Sai Life Sciences with a ‘Buy’ rating and a Rs 1,300 target price, citing its integrated ‘follow-the-molecule’ model and strong growth outlook. The brokerage highlighted the company’s healthy pipeline, global presence, and clean balance sheet as key investment drivers, projecting significant upside potential.